Published in Mol Ther on February 10, 2009
Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Sci Transl Med (2014) 2.82
Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles. Viruses (2010) 1.30
Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiol (2012) 1.28
Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J Virol (2011) 1.12
Bevacizumab with angiostatin-armed oHSV increases antiangiogenesis and decreases bevacizumab-induced invasion in U87 glioma. Mol Ther (2011) 1.04
Oncolytic viruses: From bench to bedside with a focus on safety. Hum Vaccin Immunother (2015) 1.01
Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS One (2011) 0.96
Oncolysis by paramyxoviruses: preclinical and clinical studies. Mol Ther Oncolytics (2015) 0.95
Oncolysis by paramyxoviruses: multiple mechanisms contribute to therapeutic efficiency. Mol Ther Oncolytics (2015) 0.94
Oncolytic Sindbis virus targets tumors defective in the interferon response and induces significant bystander antitumor immunity in vivo. Mol Ther (2011) 0.94
Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Cancer Biol Ther (2014) 0.92
Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head Neck (2010) 0.88
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Mol Cancer Ther (2010) 0.88
Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Cancer Gene Ther (2014) 0.88
Safety and clinical usage of newcastle disease virus in cancer therapy. J Biomed Biotechnol (2011) 0.87
Mitophagy promotes replication of oncolytic Newcastle disease virus by blocking intrinsic apoptosis in lung cancer cells. Oncotarget (2014) 0.86
Recombinant Immunomodulating Lentogenic or Mesogenic Oncolytic Newcastle Disease Virus for Treatment of Pancreatic Adenocarcinoma. Viruses (2015) 0.84
Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol (2012) 0.83
Multimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies. Front Oncol (2014) 0.83
Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol (2011) 0.82
Progress in oncolytic virotherapy for the treatment of thyroid malignant neoplasm. J Exp Clin Cancer Res (2014) 0.80
Novel oncolytic viral therapies in patients with thoracic malignancies. Oncolytic Virother (2016) 0.78
Rescue of recombinant Newcastle disease virus from cDNA. J Vis Exp (2013) 0.78
CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy. EBioMedicine (2016) 0.77
Proinflammatory response induced by Newcastle disease virus in tumor and normal cells. Oncolytic Virother (2017) 0.75
Protective efficacy of a recombinant Newcastle disease virus expressing glycoprotein of vesicular stomatitis virus in mice. Virol J (2016) 0.75
Therapeutic potential of oncolytic Newcastle disease virus: a critical review. Oncolytic Virother (2015) 0.75
Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology (1998) 9.81
Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. J Virol (2000) 6.22
Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol (2000) 5.44
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Rescue of Newcastle disease virus from cloned cDNA: evidence that cleavability of the fusion protein is a major determinant for virulence. J Virol (1999) 3.74
Recombinant Newcastle disease virus as a vaccine vector. J Virol (2001) 2.67
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Sialobiology of influenza: molecular mechanism of host range variation of influenza viruses. Biol Pharm Bull (2005) 2.58
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res (1980) 2.40
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A (2006) 2.23
NS1 protein of influenza A virus down-regulates apoptosis. J Virol (2002) 2.12
Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther (2005) 1.85
Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit. J Clin Oncol (2004) 1.84
Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol (2005) 1.78
Newcastle disease virus V protein is associated with viral pathogenesis and functions as an alpha interferon antagonist. J Virol (2003) 1.73
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res (2001) 1.66
Virulence of Newcastle disease virus is determined by the cleavage site of the fusion protein and by both the stem region and globular head of the haemagglutinin-neuraminidase protein. J Gen Virol (2005) 1.64
Newcastle disease virus (NDV): brief history of its oncolytic strains. J Clin Virol (2000) 1.61
Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Cancer Res (2007) 1.53
Generation of recombinant lentogenic Newcastle disease virus from cDNA. J Gen Virol (1999) 1.50
Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol (2006) 1.44
Engineering oncolytic measles virus to circumvent the intracellular innate immune response. Mol Ther (2007) 1.23
MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol (2004) 1.23
Phase 1 clinical experience using intravenous administration of PV701, an oncolytic Newcastle disease virus. Curr Cancer Drug Targets (2007) 1.22
Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther (2008) 1.16
Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res (2006) 1.12
Newcastle disease virus therapy of human tumor xenografts: antitumor effects of local or systemic administration. Cancer Lett (2001) 1.11
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Int J Cancer (2006) 1.08
A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res (2001) 1.04
An optimized clinical regimen for the oncolytic virus PV701. Clin Cancer Res (2007) 1.00
Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg (1998) 1.00
Interferon resistance promotes oncolysis by influenza virus NS1-deletion mutants. Int J Cancer (2004) 0.98
Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res (2004) 0.97
Antitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects. Int J Oncol (2001) 0.97
Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial. Cancer Immunol Immunother (1992) 0.97
Application of autologous tumor cell vaccine and NDV vaccine in treatment of tumors of digestive tract. World J Gastroenterol (2003) 0.96
Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res (1996) 0.93
Tumor growth retardation, cure, and induction of antitumor immunity in B16 melanoma-bearing mice by low electric field-enhanced chemotherapy. Clin Cancer Res (2003) 0.92
Fusogenic vesicular stomatitis virus for the treatment of head and neck squamous carcinomas. Otolaryngol Head Neck Surg (2007) 0.92
Treatment of stage II malignant melanoma patients with a Newcastle disease virus oncolysate. Nat Immun Cell Growth Regul (1988) 0.90
Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme. J Neurooncol (2001) 0.88
Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther (2002) 0.81
Interaction of Newcastle disease virus strains differing in virulence with chicken red blood cell receptors. Arch Virol (1985) 0.77
Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science (2005) 17.19
Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog (2007) 8.61
A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission. Science (2007) 8.38
Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. Ann Surg (2002) 8.30
Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol (2007) 7.18
Structure of the uncleaved human H1 hemagglutinin from the extinct 1918 influenza virus. Science (2004) 6.70
Genomic analysis of increased host immune and cell death responses induced by 1918 influenza virus. Nature (2006) 6.46
Glycan microarray analysis of the hemagglutinins from modern and pandemic influenza viruses reveals different receptor specificities. J Mol Biol (2005) 6.17
Transmission of influenza virus in a mammalian host is increased by PB2 amino acids 627K or 627E/701N. PLoS Pathog (2009) 6.09
Structure of an argonaute silencing complex with a seed-containing guide DNA and target RNA duplex. Nature (2008) 5.78
Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity (2013) 5.47
Structure of the guide-strand-containing argonaute silencing complex. Nature (2008) 5.36
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Human host factors required for influenza virus replication. Nature (2010) 5.28
Nucleation, propagation and cleavage of target RNAs in Ago silencing complexes. Nature (2009) 5.24
Programming the magnitude and persistence of antibody responses with innate immunity. Nature (2011) 5.18
Influenza A virus NS1 targets the ubiquitin ligase TRIM25 to evade recognition by the host viral RNA sensor RIG-I. Cell Host Microbe (2009) 5.12
Inhibition of interferon signaling by dengue virus. Proc Natl Acad Sci U S A (2003) 5.05
A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. PLoS Pathog (2007) 4.99
Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol (2007) 4.95
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virus. J Virol (2006) 4.88
H5N1 and 1918 pandemic influenza virus infection results in early and excessive infiltration of macrophages and neutrophils in the lungs of mice. PLoS Pathog (2008) 4.79
Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. J Virol (2006) 4.74
The Ebola virus VP35 protein inhibits activation of interferon regulatory factor 3. J Virol (2003) 4.73
A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. J Virol (2005) 4.71
Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc Natl Acad Sci U S A (2008) 4.67
The guinea pig as a transmission model for human influenza viruses. Proc Natl Acad Sci U S A (2006) 4.58
Newcastle disease virus (NDV)-based assay demonstrates interferon-antagonist activity for the NDV V protein and the Nipah virus V, W, and C proteins. J Virol (2003) 4.45
Inhibition of alpha/beta interferon signaling by the NS4B protein of flaviviruses. J Virol (2005) 4.31
Cellular transcriptional profiling in influenza A virus-infected lung epithelial cells: the role of the nonstructural NS1 protein in the evasion of the host innate defense and its potential contribution to pandemic influenza. Proc Natl Acad Sci U S A (2002) 4.26
Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol (2005) 4.16
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio (2010) 4.15
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe (2007) 4.14
Early and sustained innate immune response defines pathology and death in nonhuman primates infected by highly pathogenic influenza virus. Proc Natl Acad Sci U S A (2009) 4.12
Pathogenicity and immunogenicity of influenza viruses with genes from the 1918 pandemic virus. Proc Natl Acad Sci U S A (2004) 4.00
IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci U S A (2007) 3.98
Human HA and polymerase subunit PB2 proteins confer transmission of an avian influenza virus through the air. Proc Natl Acad Sci U S A (2009) 3.91
Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog (2010) 3.89
Interferon antagonist proteins of influenza and vaccinia viruses are suppressors of RNA silencing. Proc Natl Acad Sci U S A (2004) 3.85
Ebola virus VP35 protein binds double-stranded RNA and inhibits alpha/beta interferon production induced by RIG-I signaling. J Virol (2006) 3.84
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
Matrix protein 2 of influenza A virus blocks autophagosome fusion with lysosomes. Cell Host Microbe (2009) 3.79
High temperature (30 degrees C) blocks aerosol but not contact transmission of influenza virus. J Virol (2008) 3.77
Seroevidence for H5N1 influenza infections in humans: meta-analysis. Science (2012) 3.74
Gain-of-function experiments on H7N9. Science (2013) 3.67
Multiple anti-interferon actions of the influenza A virus NS1 protein. J Virol (2007) 3.53
Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. PLoS Pathog (2005) 3.44
A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol (2003) 3.44
A selective approach to the resection of cystic lesions of the pancreas: results from 539 consecutive patients. Ann Surg (2006) 3.34
Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci U S A (2010) 3.24
Analysis of in vivo dynamics of influenza virus infection in mice using a GFP reporter virus. Proc Natl Acad Sci U S A (2010) 3.17
Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg (2008) 3.16
Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science (2007) 3.16
Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann Surg (2003) 3.14
Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical swine H1N1 based vaccines. PLoS Pathog (2010) 3.08
Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat Immunol (2007) 3.04
Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respir Viruses (2012) 3.04
Influenza A viruses: new research developments. Nat Rev Microbiol (2011) 3.00
Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. Cancer (2003) 2.96
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Influenza virus evades innate and adaptive immunity via the NS1 protein. J Virol (2006) 2.94
Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J Virol (2005) 2.88
Preference of RIG-I for short viral RNA molecules in infected cells revealed by next-generation sequencing. Proc Natl Acad Sci U S A (2010) 2.81
Severe acute respiratory syndrome coronavirus open reading frame (ORF) 3b, ORF 6, and nucleocapsid proteins function as interferon antagonists. J Virol (2006) 2.78
Single gene reassortants identify a critical role for PB1, HA, and NA in the high virulence of the 1918 pandemic influenza virus. Proc Natl Acad Sci U S A (2008) 2.72
Live attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenza. J Virol (2008) 2.71
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
Specific residues of the influenza A virus hemagglutinin viral RNA are important for efficient packaging into budding virions. J Virol (2007) 2.62
Newcastle disease virus V protein is a determinant of host range restriction. J Virol (2003) 2.61
Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J Virol (2006) 2.61
The biology of influenza viruses. Vaccine (2008) 2.58
American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol (2009) 2.52